Company Overview
Rallybio Corporation, a clinical-stage biotechnology company, engages in the development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is the RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB332, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. The company has a strategic alliance with AbCellera to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases, as well as collaboration agreement with Johnson & Johnson to provide therapeutic solutions for pregnant individuals at risk of fetal and neonatal alloimmune thrombocytopenia. Rallybio Corporation was founded in 2018 and is headquartered in New Haven, Connecticut.
Why Investors Should Care
Generates a return on equity of 64.9%, reflecting efficient use of shareholder capital.
Trades at a P/E of 2.1, below the sector median of 24.8.
Carries low leverage with a debt-to-equity ratio of 0.31.
Recent Developments
- Dec 2025 Revenue of $858.00K (+34.9% YoY); net profit $-8.98M.
- Trailing 12 Months Year-on-year growth — revenue +0.0%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | - |
| 1 Year: | 0.00% |
Stock Price Performance
| 1 Year: | +288.08% |
| 6 Months: | +54.30% |
| 3 Months: | +4.40% |
| 1 Month: | +2.78% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)49.19 · Neutral
P/E of 2.08 is below the sector median of 24.83 — relatively cheaper than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Strong return on equity of 64.9%.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | RLYB Rallybio Corporation PHARMA | 16.61 | 2.08 | $88.24M | 0.00% | -56.97% | 64.86% | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 299.00K | 299.00K | - | 212.00K | 212.00K | 212.00K | 222.00K | 212.00K |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 9.88M | 10.27M | 7.14M | 6.63M | 8.95M |
| Operating Income | -4.66M | -6.71M | -12.82M | -10.53M | -9.98M | -14.32M | -17.61M | -18.86M | -18.37M | -20.08M | -19.36M | -19.79M | -17.04M | -12.07M | - | -9.67M | -10.06M | -6.92M | -6.41M | -8.73M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -9.64M | -10.03M | -6.89M | -6.41M | -8.73M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -9.44M | -9.42M | 16.02M | -5.85M | -8.28M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Income | -4.89M | -7.16M | -13.28M | -11.13M | -10.20M | -14.50M | -17.58M | -18.37M | -17.32M | -18.63M | -18.37M | -19.03M | -16.24M | -11.47M | - | -9.44M | -9.70M | 16.02M | -5.85M | -8.28M |
| Diluted EPS | - | - | - | -0.49 | -0.37 | -0.48 | -0.57 | -0.60 | -0.43 | -0.46 | -0.45 | -0.47 | -0.37 | -0.26 | -2.00 | -1.68 | -1.76 | 2.88 | - | -1.46 |
| R&D Expense | 3.09M | 5.13M | 9.04M | 6.82M | 4.96M | 7.65M | 10.14M | 12.11M | 11.20M | 13.13M | 13.29M | 12.94M | 12.95M | 8.24M | - | 5.72M | 6.07M | 4.14M | - | 2.87M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Revenue | - | - | 0 | 0 | 636.00K | 858.00K |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| Operating Expenses | - | - | 67.88M | 78.93M | 61.13M | 33.92M |
| Operating Income | -25.30M | - | -67.88M | -78.93M | -60.50M | -33.06M |
| EBITDA | - | - | -67.72M | -78.78M | -60.37M | -32.97M |
| Interest Expense | - | 10.00K | 0 | - | - | - |
| Pretax Income | - | - | -66.65M | -74.56M | -57.77M | -8.98M |
| Tax Provision | - | 0 | - | - | - | - |
| Net Income | -26.45M | - | -66.65M | -74.56M | -57.77M | -8.98M |
| Diluted EPS | - | - | -16.72 | -14.72 | -10.64 | -1.59 |
| R&D Expense | 17.63M | 26.91M | 40.69M | 53.54M | 41.51M | 19.60M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Total Assets | - | 141.86M | - | 180.44M | 115.62M | 68.11M | 62.26M |
| Current Assets | - | - | - | 179.50M | 114.79M | 67.84M | 61.25M |
| Cash & Equivalents | - | 140.23M | - | 56.96M | 24.49M | 13.90M | 31.37M |
| Inventory | - | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | - | - |
| Total Liabilities | - | 5.86M | - | 11.12M | 9.44M | 6.45M | 4.30M |
| Current Liabilities | - | 5.84M | - | 10.74M | 9.26M | 6.24M | 4.22M |
| Long Term Debt | - | - | - | - | - | - | - |
| Total Debt | - | - | - | 555.00K | 392.00K | 154.00K | 176.00K |
| Total Equity | 16.86M | 136.00M | - | 169.32M | 106.18M | 61.65M | 57.96M |
| Shares Outstanding | - | - | - | 4.73M | 4.73M | 5.19M | 5.28M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -22.04M | - | -57.28M | -60.27M | -49.28M | -29.81M |
| Investing Cash Flow | -2.07M | - | -112.17M | 27.66M | 33.49M | 47.27M |
| Financing Cash Flow | 144.89M | - | 51.08M | 143.00K | 5.20M | 16.00K |
| Capital Expenditure | -137.00K | -333.00K | -54.00K | -12.00K | - | - |
| Free Cash Flow | -22.18M | - | -57.34M | -60.28M | -49.28M | -29.81M |
| Net Change in Cash | - | - | -118.38M | -32.46M | -10.59M | 17.47M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | -9,511.9% | -3,853.6% |
| Net Margin % | - | - | - | - | -9,084.1% | -1,046.4% |
| ROE % | -19.4% | - | -39.4% | -70.2% | -93.7% | -15.5% |
| ROCE % | -18.6% | - | -40.0% | -74.2% | -97.8% | -57.0% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Adar1 Capital Management, LLC | 17.44% | 926.35K | $15.92M |
| 2 | FMR, LLC | 14.97% | 794.72K | $13.66M |
| 3 | Viking Global Investors, L.P. | 9.87% | 524.35K | $9.01M |
| 4 | TPG GP A, LLC | 7.13% | 378.55K | $6.51M |
| 5 | Pivotal bioVenture Partners Investment Advisor, LLC | 5.66% | 300.58K | $5.17M |
| 6 | Renaissance Technologies, LLC | 3.76% | 199.91K | $3.44M |
| 7 | Nantahala Capital Management, LLC | 3.55% | 188.42K | $3.24M |
| 8 | Vanguard Capital Management LLC | 3.25% | 172.50K | $2.97M |
| 9 | Almitas Capital LLC | 2.27% | 120.68K | $2.07M |
| 10 | Rangeley Capital, LLC | 1.97% | 104.85K | $1.80M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for RLYB
RLYB Stock Hits 2-Year Highs After Unveiling Merger With Avenzo – How Much Of The New Company Will Rallybio Shareholders Own? - Stocktwits
<a href="https://news.google.com/rss/articles/CBMioAFBVV95cUxOcGNnTVI4djY2SkhCTHEyNGZpcHVYd1N0YVlRVllqVWVob05leHY0U1hIU3hEeUFoWGJWNklEaThtd3JZZVpGRUo2NEhsOV9yc3BvTXJMcG85Nl9oYnlGWEtHMVE5aTRNWnFjWTVNWGVCTHkzN1FlLUJBOHFVM1k0SEpwbEJGbWhOYkVuaz…
Discipline and Rules-Based Execution in RLYB Response - Stock Traders Daily
<a href="https://news.google.com/rss/articles/CBMizgFBVV95cUxPdmVfMXcwTXVyN1pELVZWaEp3SFJ1QzhwRjdKcWlvNmE1WmdLSGZxdHdPNnFNMTk2cDdzbG1TWTJxMjNCWTFWRVlNcXM1QkhsY3lPUDJEdmM5Y20xc1ZwQUhXdFJfbDBPaGlZY2sxS3hkYVVrQXZpbjFnT1hQMGd2WWZ1MVhpckMtUDZtbX…
RLYB Stock Hits 2-Year Highs After Unveiling Merger With Avenzo – How Much Of The New Company Will Rallybio Shareholders Own? - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMikgFBVV95cUxQSVdacmdSc2ZNZDdYS0hubjJiVDhuZGF4QWZNdnNIWjUyQmQyN0p4UzhKOUlCdG1kN2VVT0Zod0lPelFhV0JDQUJvSWZXbk5kamxKSWZwRjJCclBqSnBQZ1R5RWRZeS1oa3p4eEhrNm9qM2lGcjVYRnJUb0xlN2RteXpTXzhNam9rQmpGVj…
Rallybio Corp (NASDAQ: RLYB) Stock Price, News & Analysis - kalkine.com.au
<a href="https://news.google.com/rss/articles/CBMiVkFVX3lxTE5lQXpSaUU4enJROTVId2xPaVEzZ2NyOFJKbTdfM2FiZy03MHV4Ri04UWNoX0FhSXAwdjZmMG1pRVBBY2llYk84SnFfeHB1WVJ4LUVvZE9R?oc=5" target="_blank">Rallybio Corp (NASDAQ: RLYB) Stock Price, News & An…
Rallybio Stock (RLYB) Opinions on Merger Termination Fee and Insider Buys | RLYB Stock News - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMirwFBVV95cUxNVTdoekloU291TzhXbUNGbm9tQm9zdFdIVXVtV3pjYlBWOUozOUdUS1RZTWUzbFVndllPSGM3UFUxaUlUd1lMeS15alUxcFVibVdHeW9tOHlYcmt0enJXNVNBMkJBOHJ0bFF2dnJmN1gxWWk5UGhMTXlxeGt5UUhBNFFrdkN5SUxPNnlDY3…
Rallybio Corp (RLYB) Debt 2025 - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiXEFVX3lxTFBIMDNqWWtha0txYVE4SGRxMTNTUUpmdHdvcEtMTDUweUtUUzJyUHAtWEpNWFhnaVV5dVVGVmh1RmhFTWJOVEtFVUhxYVQzSURKdXFiWXhTSmJha2cw?oc=5" target="_blank">Rallybio Corp (RLYB) Debt 2025</a> &nb…
RLYB — Frequently Asked Questions
What is the current share price of Rallybio Corporation (RLYB)?
As of 2026-09-19 21:16 PDT, Rallybio Corporation (RLYB) trades at $16.61 on NasdaqCM. Its 52-week range is $3.99 to $17.00.
What is the market capitalisation of RLYB?
Rallybio Corporation (RLYB) has a market capitalisation of $88.24M on NasdaqCM.
What is the P/E ratio of RLYB?
RLYB trades at a trailing price-to-earnings (P/E) ratio of 2.08. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 0.97.
What is the return on equity (ROE) of RLYB?
RLYB has a return on equity (ROE) of 64.86%. Its return on capital employed (ROCE) is -56.97%.
Is RLYB a good stock to buy?
This page provides a data-driven analysis of Rallybio Corporation (RLYB), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.